A new phase 1 clinical trial of a potential vaccine for the SARS-CoV2 coronavirus began on Monday in Seattle, as the first person to enroll in the trial received the vaccine.
The vaccine, mRNA-1273, was developed by biotechnology company Moderna in combination with researchers from the National Institutes of Health (NIH).
The trial is being conducted at Kaiser Permanente Washington Health Research Institute in Seattle.
The phase 1 study aims to test three different doses of the mRNA-1273 vaccine ad hopes to recruit 45 healthy adults for the initial trial.
Participants will receive two shots of the vaccine, 28 days apart and will be monitored to evaluate both the safety and immunogenicity of the vaccine.
The latter involves seeing how well the vaccine stimulates an immune response to a protein on the SARS-CoV2 coronavirus surface.
The first person to get the vaccine was 43-year old Jennifer Haller from Seattle who said; “I hope that we get to a working vaccine quickly and that we can save lives and people can go back to life as soon as possible,” in an in an interview with TIME
“This study is the first step in the clinical development of an mRNA vaccine against SARS-CoV-2, and we expect it to provide important information about safety and immunogenicity,” said Tal Zaks, M.D., Ph.D., Chief Medical Officer at Moderna in a press release. He added that Moderna is already working with the FDA and other organizations to prepare for a phase 2 trial, which would involve larger numbers of patients.